Millipore Sigma Vibrant Logo

528205 Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: PAI-1

Primary Target: Tissue plasminogen activator (tPA) and urokinase (uPA)
View Products on Sigmaaldrich.com
528205
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
528205-50UG
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 50 μg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewPAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
      Catalogue Number528205
      Brand Family Calbiochem®
      SynonymsPAI-1
      References
      ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
      Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
      Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
      Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
      Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
      Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
      Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
      Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
      Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
      Product Information
      ATP CompetitiveN
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
      ReversibleN
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetTissue plasminogen activator (tPA) and urokinase (uPA)
      Purity≥95% by SDS-PAGE
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      528205-50UG 04055977196481

      Documentation

      Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem Certificates of Analysis

      TitleLot Number
      528205

      References

      Reference overview
      Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
      Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
      Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
      Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
      Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
      Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
      Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
      Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
      Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision24-August-2023 JSW
      SynonymsPAI-1
      DescriptionPrimary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α2-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
      Purity≥95% by SDS-PAGE
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesVaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
      Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
      Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
      Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
      Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
      Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
      Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
      Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
      Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.